| scholarly article | Q13442814 |
| P50 | author | Tami Pilot-Matias | Q47412244 |
| Carolyn Setze | Q47412541 | ||
| Kazuaki Chayama | Q87781872 | ||
| Hiromitsu Kumada | Q114433568 | ||
| P2093 | author name string | Regis A Vilchez | |
| Ken Sato | |||
| Masayuki Kurosaki | |||
| Prajakta Badri | |||
| Kazuo Notsumata | |||
| Lino Rodrigues | |||
| P2860 | cites work | Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 |
| Epidemiology of viral hepatitis and hepatocellular carcinoma | Q29617918 | ||
| Telaprevir for retreatment of HCV infection | Q29619799 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options | Q29620126 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection | Q29620620 | ||
| Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region | Q34998753 | ||
| Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study | Q37491370 | ||
| Changing trends in hepatitis C infection over the past 50 years in Japan | Q37672875 | ||
| In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. | Q38934649 | ||
| In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. | Q41633072 | ||
| Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection | Q41729517 | ||
| All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study | Q42202767 | ||
| ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. | Q42219325 | ||
| Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). | Q42220208 | ||
| Sofosbuvir and ribavirin in HCV genotypes 2 and 3. | Q42220605 | ||
| ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. | Q42220608 | ||
| Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial | Q42224933 | ||
| ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis | Q42225140 | ||
| Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin | Q42225540 | ||
| Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin | Q42225545 | ||
| Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. | Q42243136 | ||
| Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy. | Q42983726 | ||
| Development and evaluation of an automated hepatitis C virus NS5B sequence-based subtyping assay | Q42998028 | ||
| Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. | Q43001836 | ||
| Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan | Q43039581 | ||
| Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. | Q45009249 | ||
| Epidemiology of hepatitis C virus in japan | Q45746821 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ribavirin | Q421862 |
| ritonavir | Q422618 | ||
| Hepatitis C virus | Q708693 | ||
| paritaprevir | Q16824572 | ||
| ombitasvir | Q19598175 | ||
| ombitasvir/paritaprevir/ritonavir | Q19858657 | ||
| P304 | page(s) | 1523-1532 | |
| P577 | publication date | 2015-03-23 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients | |
| P478 | volume | 61 |
| Q49446996 | A Hepatitis C Virus-Associated Chronic Hepatitis Patient Developing Various Adverse Events Including Severe Gingivitis, Gingival Bleeding, and Inflammation of Genital Vulva during the Course of Antiviral Therapy with Elbasvir/Grazoprevir |
| Q40130081 | A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir |
| Q42400012 | APASL consensus statements and recommendation on treatment of hepatitis C. |
| Q40071581 | Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report. |
| Q40116908 | Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. |
| Q26773274 | Alcoholic liver disease and hepatitis C virus infection |
| Q38367590 | Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir |
| Q40548267 | Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens |
| Q39147495 | Clinical Pharmacokinetics of Ombitasvir |
| Q39150134 | Clinical Pharmacokinetics of Paritaprevir |
| Q39151677 | Current therapy for chronic hepatitis C: The role of direct-acting antivirals |
| Q36438920 | Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir |
| Q40697687 | Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir |
| Q37067118 | Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers |
| Q36571969 | Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir |
| Q50208930 | Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. |
| Q47888797 | Efficacy and safety of telaprevir with natural human interferon-β and ribavirin in Japanese chronic hepatitis C patients with depression |
| Q40721350 | Efficacy and safety of telaprevir with pegylated interferon α-2a and ribavirin in Japanese patients |
| Q38837174 | Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. |
| Q26782405 | HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy |
| Q49238531 | Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients. |
| Q36933403 | Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle. |
| Q55280981 | Host-targeting therapies for hepatitis C virus infection: current developments and future applications. |
| Q40827559 | IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. |
| Q59354172 | Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era |
| Q40791531 | JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2. |
| Q27469038 | Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance |
| Q40621621 | Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment |
| Q39675766 | Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection. |
| Q26775825 | Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection |
| Q40533002 | Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing |
| Q38376454 | Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients |
| Q37309080 | Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis |
| Q26750476 | Recent Advances in Antiviral Therapy for Chronic Hepatitis C |
| Q40069650 | Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir. |
| Q40058097 | Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis |
| Q40413390 | Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. |
| Q38903835 | Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. |
| Q36290778 | Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance |
| Q39483711 | Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. |
| Q59360750 | The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1 |
| Q58088666 | The complex association of virus- and host-related factors with HCC rate following HCV clearance |
| Q40340001 | The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings |
| Q90134965 | The reduction of miR146b-5p in monocytes and T cells could contribute to the immunopathogenesis of hepatitis C virus infection |
| Q40087272 | The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. |
| Q45078816 | Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir |
| Q38431523 | Treatment of hepatitis C in difficult-to-treat patients |
Search more.